The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.

Alex J LiuHeidi E KosiorekBenjamin E UeberrothEllen JaegerElisa M LedetAyse T KendiKatherine TzouFernando QuevedoRichard ChooCassandra N MooreThai H HoParminder SinghSameer R KeoleWilliam W Wong A Oliver Sartor Alan H Bryce

Published in: The Prostate (2022)

Among mCRPC patients treated with Ra-223 at Mayo Clinic and Tulane Cancer Center, we did not find any clear negative predictors of biochemical response or survival to treatment. TMPRSS2-ERG and RB mutations were associated with a worse OS. Prospective studies and larger sample sizes are needed to determine the impact of genetic aberrations in response to Ra-223.

Keyphrases

copy number
rheumatoid arthritis
primary care
genome wide
squamous cell carcinoma
gene expression
combination therapy
ankylosing spondylitis
case control